SPOTLIGHT: GSK allows generic AIDS drug

GlaxoSmithKline says it's letting a Canadian drug company use two of its patented drugs in a combination HIV therapy for Rwanda. Apotex will make the combo--known as Apo-triAvir--using Glaxo's antiretrovirals lamivudine and zidovudine, plus Boehringer Ingelheim's nevirapine. The agreement was struck through Canada's Access to Medicines initiative, a three-year-old bit of legislation intended to help poor countries gain access to needed drugs, but until now has failed to do so. Report

Suggested Articles

Novavax has inked a $60 million contract with the U.S. Department of Defense to help fund U.S.-based manufacturing of its COVID-19 vaccine candidate.

Since the Warp Speed selections went public, experts have been wondering why some drugmakers were left off.

Vaccine maker Inovio has accused a longtime manufacturing partner of hampering its efforts to produce 1 million doses of a potential COVID-19 vaccine.